Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
274,650,631
-
Total 13F shares
-
167,089,013
-
Share change
-
+11,306,475
-
Total reported value
-
$289,098,804
-
Put/Call ratio
-
16%
-
Price per share
-
$1.73
-
Number of holders
-
125
-
Value change
-
+$18,983,328
-
Number of buys
-
66
-
Number of sells
-
42
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock (TSHA) as of Q4 2024
As of 31 Dec 2024,
Taysha Gene Therapies, Inc. - Common Stock (TSHA) was held by
125 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
167,089,013 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, MORGAN STANLEY, FMR LLC, BlackRock, Inc., RA CAPITAL MANAGEMENT, L.P., Octagon Capital Advisors LP, VANGUARD GROUP INC, RTW INVESTMENTS, LP, Siren, L.L.C., and STATE STREET CORP.
This page lists
126
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.